430 related articles for article (PubMed ID: 32079420)
21. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
[TBL] [Abstract][Full Text] [Related]
22. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
23. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
[TBL] [Abstract][Full Text] [Related]
24. FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats.
Lövgren KM; Larsen MS; Zintner SM; Small JC; Kjelgaard-Hansen M; Häger M; Petersen M; Wiinberg B; Margaritis P
J Thromb Haemost; 2020 Jul; 18(7):1586-1597. PubMed ID: 32196903
[TBL] [Abstract][Full Text] [Related]
25. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.
Sarkar R; Tetreault R; Gao G; Wang L; Bell P; Chandler R; Wilson JM; Kazazian HH
Blood; 2004 Feb; 103(4):1253-60. PubMed ID: 14551134
[TBL] [Abstract][Full Text] [Related]
26. CTLA4-Ig prevents development of neutralizing antibody formation after continuous treatment with human FVIII in HA rats.
Øvlisen GO; Thygesen P; Weldingh KN; Bloem E; Skov S; Almholt K; Lövgren KM; Ley CD; Holm TL
Haemophilia; 2022 Jul; 28(4):568-577. PubMed ID: 35467059
[TBL] [Abstract][Full Text] [Related]
27. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
Patel SR; Lundgren TS; Spencer HT; Doering CB
Front Immunol; 2020; 11():494. PubMed ID: 32351497
[TBL] [Abstract][Full Text] [Related]
28. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
[TBL] [Abstract][Full Text] [Related]
29. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.
Siner JI; Samelson-Jones BJ; Crudele JM; French RA; Lee BJ; Zhou S; Merricks E; Raymer R; Nichols TC; Camire RM; Arruda VR
JCI Insight; 2016 Oct; 1(16):e89371. PubMed ID: 27734034
[TBL] [Abstract][Full Text] [Related]
30. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
[TBL] [Abstract][Full Text] [Related]
31. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
[TBL] [Abstract][Full Text] [Related]
32. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.
Lai JD; Moorehead PC; Sponagle K; Steinitz KN; Reipert BM; Hough C; Lillicrap D
Blood; 2016 Jun; 127(26):3439-49. PubMed ID: 27034428
[TBL] [Abstract][Full Text] [Related]
33. IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia.
Narkbunnam N; Sun J; Hu G; Lin FC; Bateman TA; Mihara M; Monahan PE
J Thromb Haemost; 2013 May; 11(5):881-93. PubMed ID: 23413986
[TBL] [Abstract][Full Text] [Related]
34. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice.
Lundgren TS; Denning G; Stowell SR; Spencer HT; Doering CB
Blood Adv; 2022 Apr; 6(8):2628-2645. PubMed ID: 35286375
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.
Batty P; Mo AM; Hurlbut D; Ishida J; Yates B; Brown C; Harpell L; Hough C; Pender A; Rimmer EK; Sardo Infirri S; Winterborn A; Fong S; Lillicrap D
Blood; 2022 Dec; 140(25):2672-2683. PubMed ID: 35405003
[TBL] [Abstract][Full Text] [Related]
37. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
Sun J; Hakobyan N; Valentino LA; Feldman BL; Samulski RJ; Monahan PE
Blood; 2008 Dec; 112(12):4532-41. PubMed ID: 18716130
[TBL] [Abstract][Full Text] [Related]
38. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
[TBL] [Abstract][Full Text] [Related]
39. The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy.
Youjin S; Jun Y
Biotechnol Lett; 2009 Mar; 31(3):321-8. PubMed ID: 18979215
[TBL] [Abstract][Full Text] [Related]
40. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
